C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 312—Investigational New Drug ApplicationSubpart B—Investigational New Drug Application (Ind)

21 C.F.R. § 312.20 (2026)

Requirement for an IND

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1985–2024 10citing cases
At a glance

Courts have cited this section in 10 opinions since 1985, 2 of them in the last five years.

(a) A sponsor shall submit an IND to FDA if the sponsor intends to conduct a clinical investigation with an investigational new drug that is subject to § 312.2(a).

(b) A sponsor shall not begin a clinical investigation subject to § 312.2(a) until the investigation is subject to an IND which is in effect in accordance with § 312.40.

(c) A sponsor shall submit a separate IND for any clinical investigation involving an exception from informed consent under § 50.24 of this chapter. Such a clinical investigation is not permitted to proceed without the prior written authorization from FDA. FDA shall provide a written determination 30 days after FDA receives the IND or earlier.

[52 FR 8831, Mar. 19, 1987, as amended at 61 FR 51529, Oct. 2, 1996; 62 FR 32479, June 16, 1997]
The 10 cases that cite 21 C.F.R. § 312.20 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBrennan v. Zafgen, Inc., 853 F.3d 606 (1st Cir. 2017).
cites § 312.20 1×cited by 32 cases
Where it cites § 312.20
“; see also 21 C.F.R. § 312.20 . If the FDA approves that request, human testing begins.”
The case’s holding
A complaint lacking direct evidence of scienter must rely on indirect evidence that is sufficient to raise a strong inference of fraudulent intent.
Later courts cite it for
“where a complaint is devoid of any direct-evidence allegations, the indirect-evidence allegations in the complaint will need to do more work to carry the burden of raising a 'strong inference of scienter' on their own.” · 3 citing courts
cites § 312.20 1×cited by 63 cases
Where it cites § 312.20
“; see also 21 C.F.R. § 312.20 . If this request is approved, human testing begins, and typically follows three phases, commonly known as clinical trials.”
The case’s holding
A statement is not intentionally misleading if the defendant lacks sufficient information at the relevant time to form an intent not to disclose certain information.
Later courts cite it for
“a statement cannot be intentionally misleading if the defendant did not have sufficient information at the relevant time to form an evaluation that there was a need to disclose certain information and to form an intent not to disclose it.” · 9 citing courts
3
GREENMiller v. Pfizer Inc.(Roerig Div.), 196 F. Supp. 2d 1095 (D. Kan. 2002).
cites § 312.20 2×cited by 10 cases
Where it cites § 312.20
“See 21 C.F.R. §§ 312.20 , 312.21. 17 . See 21 C.”
4
GREENMohr v. Targeted Genetics, Inc., 690 F. Supp. 2d 711 (C.D. Ill. 2010).
cites § 312.20 2×cited by 2 cases
Where it cites § 312.20
“See 21 C.F.R. § 312.20 . Before filing the IND, the applicant must have subjected biologically active agents of the proposed drug to comprehensive animal and human tissue testing.”
5
GREENUnited States v. An Article of Device ... Diapulse, 768 F.2d 826 (7th Cir. 1985).
cites § 312.20 1×cited by 8 cases
Where it cites § 312.20
“1 (a)(12) and (13), forms FD-1572 and FD-1573 6g; 21 C.F.R. § 312.20 (Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects), 1.”
6
GREENEUSA Pharma (US), Inc. v. Innocoll Pharm. Ltd., 594 F. Supp. 2d 570 (E.D. Pa. 2009).
cites § 312.20 1×cited by 1 case
Where it cites § 312.20
“21 C.F.R. § 312.20 (a). Second, an Investiga-tional Review Board must approve the trial after reviewing its protocol and past clinical trials on animals.”
7
GREENCowan v. United States, 5 F. Supp. 2d 1235 (N.D. Okla. 1998).
cites § 312.20 1×cited by 1 case
Summary
No passage or summary on file for this case yet.
8
NO FLAGIn re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-cv-00182 (S.D. Cal. Sept. 5, 2019).
cites § 312.20 1×cited by 0 casesunknown
Where it cites § 312.20
“14 See 21 C.F.R. §§ 312.20 , 312.40. Generally, an IND must contain, inter alia, “[a] 15 summary of the pharmacological and toxicological effects of the drug in animals, 16 and to the extent known, in humans.”
9
NO FLAGKarimian v. Alkermes Pub. Ltd. Co., No. 1:18-cv-07410 (E.D.N.Y. Feb. 26, 2021).
cites § 312.20 1×cited by 0 casesunknown
Where it cites § 312.20
“21 C.F.R. § 312.20 . A clinical investigation is generally divided into three phases.”
10
NO FLAGAn opinion was released in case 23-5200 v. FDA, No. 23-5200 (D.C. Cir. Dec. 17, 2024).
cites § 312.20 1×cited by 0 cases
Where it cites § 312.20
“§ 355(i)(1), 21 C.F.R. § 312.20 (a). The IND allows manufacturers to run clinical trials before obtaining marketing approval.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198520042024

One bar per year. Tallest: 1 case in 1985. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
1st Cir.27th Cir.1D.C. Cir.1S.D. Cal.1C.D. Ill.1D. Kan.1E.D.N.Y1N.D. Okla.1

The 8 courts with the most citing cases, of 9 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com